drugset / Trial / NCT01408095
A Study in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed to see if once daily oral dosing of LY2608204 will help control diabetes as measured by the glycosylated fraction of hemoglobin A (HbA1c) level. It will also help to determine the safety of the medication and the most useful doses of the medication.
Timeline
- Start
- 2011-09
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glimepiride | Small molecule | — | Oral |
| Subject | LY2608204 | Small molecule | — | Oral |